Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient samples

Zhang, Chen; Zhang, Jiandong; Fan, Li; Guo, Han; Gao, Shiqian; Yang, Fuwei; Guo, Hua; Wang, Guizhen; Wang, Wei; Zhou, Guang‐Biao

doi:10.1007/s11684-021-0868-z

Cited by 14 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD24 is highly expressed on the surface of tumor cells and inhibits tumor cell phagocytosis by macrophages through binding to the inhibitory receptor Siglec10, which is highly expressed on the surface of macrophages. Siglec10, a member of the natural immune checkpoint, is a sialic acid binding Ig-like lectin 10, an inhibitory receptor recognized by sialic acid that regulates antibody production against sialylated antigens [ 184 , 185 ]. In ovarian, triple-negative breast, and renal clear cell carcinomas, Siglec10 interacts with CD24 to inhibit immune cell activation and tumor cell phagocytosis.…”

Section: Strategies For Targeting Macrophages In the Treatment Of Sol...mentioning

confidence: 99%

Targeting macrophages: a novel treatment strategy in solid tumors

Liu

Song

et al. 2022

J Transl Med

View full text Add to dashboard Cite

In the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are the most abundant immune cells, which act as a key regulator in tumorigenesis and progression. Increasing evidence have demonstrated that the TME alters the nature of macrophages to maintain dynamic tissue homeostasis, allowing TAMs to acquire the ability to stimulate angiogenesis, promote tumor metastasis and recurrence, and suppress anti-tumor immune responses. Furthermore, tumors with high TAM infiltration have poor prognoses and are resistant to treatment. In the field of solid tumor, the exploration of tumor-promoting mechanisms of TAMs has attracted much attention and targeting TAMs has emerged as a promising immunotherapeutic strategy. Currently, the most common therapeutic options for targeting TAMs are as follows: the deletion of TAMs, the inhibition of TAMs recruitment, the release of phagocytosis by TAMs, and the reprogramming of macrophages to remodel their anti-tumor capacity. Promisingly, the study of chimeric antigen receptor macrophages (CAR-Ms) may provide even greater benefit for patients with solid tumors. In this review, we discuss how TAMs promote the progression of solid tumors as well as summarize emerging immunotherapeutic strategies that targeting macrophages.

show abstract

Section: Strategies For Targeting Macrophages In the Treatment Of Sol...mentioning

confidence: 99%

Targeting macrophages: a novel treatment strategy in solid tumors

Liu

Song

et al. 2022

J Transl Med

View full text Add to dashboard Cite

show abstract

“…In addition, the surface expression of CD24 has been described as a “do not eat me” signal, inhibiting phagocytosis by infiltrating Siglec-10-expressing macrophages [ 30 ]. In contrast, the loss of CD24 expression has been shown to increase phagocytosis by macrophages expressing Siglec-10 in renal clear cell carcinoma [ 79 ]. Furthermore, a decrease in Siglec binding to surface sialic acids promotes macrophage-mediated phagocytosis [ 80 ].…”

Section: Implications In Antitumor Immunitymentioning

confidence: 99%

CD24: A Novel Target for Cancer Immunotherapy

Panagiotou

Syrigos

Charpidou

et al. 2022

JPM

View full text Add to dashboard Cite

Cluster of differentiation 24 (CD24) is a small, highly glycosylated cell adhesion protein that is normally expressed by immune as well as epithelial, neural, and muscle cells. Tumor CD24 expression has been linked with alterations in several oncogenic signaling pathways. In addition, the CD24/Siglec-10 interaction has been implicated in tumor immune evasion, inhibiting macrophage-mediated phagocytosis as well as natural killer (NK) cell cytotoxicity. CD24 blockade has shown promising results in preclinical studies. Although there are limited data on efficacy, monoclonal antibodies against CD24 have demonstrated clinical safety and tolerability in two clinical trials. Other treatment modalities evaluated in the preclinical setting include antibody–drug conjugates and chimeric antigen receptor (CAR) T cell therapy. In this review, we summarize current evidence and future perspectives on CD24 as a potential target for cancer immunotherapy.

show abstract

Section: Immune Checkpointsmentioning

confidence: 99%

“…Sialic acid binding Ig like lectin 10 (Siglec10), is predominantly expressed on innate immune cells such as macrophages [ 118 , 119 ], dendritic cells [ 120 ], and NK cells [ 121 ]. It acts as an innate immune checkpoint by interacting with its ligand CD24 present on tumor cells, leading to the functional inactivation of immune cells [ 118 , 122 ]. Multiple tumors have been shown to have altered Siglec10 expression [ 118 ], and an elevated expression in patients with kidney renal clear cell carcinoma (KIRC) negatively correlates with the survival of patients [ 118 ].…”

Section: Immune Checkpointsmentioning

confidence: 99%

“…It acts as an innate immune checkpoint by interacting with its ligand CD24 present on tumor cells, leading to the functional inactivation of immune cells [ 118 , 122 ]. Multiple tumors have been shown to have altered Siglec10 expression [ 118 ], and an elevated expression in patients with kidney renal clear cell carcinoma (KIRC) negatively correlates with the survival of patients [ 118 ]. A recent study by Barkal et al has demonstrated a crucial role of the Siglec10-CD24 axis in the evasion of cellular phagocytosis by tumor-associated macrophages [ 122 ].…”

Section: Immune Checkpointsmentioning

confidence: 99%

See 1 more Smart Citation

Emerging Trends in Immunotherapy for Cancer

et al. 2022

View full text Add to dashboard Cite

Recent advances in cancer immunology have enabled the discovery of promising immunotherapies for various malignancies that have shifted the cancer treatment paradigm. The innovative research and clinical advancements of immunotherapy approaches have prolonged the survival of patients with relapsed or refractory metastatic cancers. Since the U.S. FDA approved the first immune checkpoint inhibitor in 2011, the field of cancer immunotherapy has grown exponentially. Multiple therapeutic approaches or agents to manipulate different aspects of the immune system are currently in development. These include cancer vaccines, adoptive cell therapies (such as CAR-T or NK cell therapy), monoclonal antibodies, cytokine therapies, oncolytic viruses, and inhibitors targeting immune checkpoints that have demonstrated promising clinical efficacy. Multiple immunotherapeutic approaches have been approved for specific cancer treatments, while others are currently in preclinical and clinical trial stages. Given the success of immunotherapy, there has been a tremendous thrust to improve the clinical efficacy of various agents and strategies implemented so far. Here, we present a comprehensive overview of the development and clinical implementation of various immunotherapy approaches currently being used to treat cancer. We also highlight the latest developments, emerging trends, limitations, and future promises of cancer immunotherapy.

show abstract

Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient samples

Cited by 14 publications

References 35 publications

Targeting macrophages: a novel treatment strategy in solid tumors

Targeting macrophages: a novel treatment strategy in solid tumors

CD24: A Novel Target for Cancer Immunotherapy

Emerging Trends in Immunotherapy for Cancer

Contact Info

Product

Resources

About